Citi lowered the firm’s price target on Haemonetics (HAE) to $64 from $78 and keeps a Buy rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance
- Haemonetics’ Earnings Call: Growth Amid Challenges
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
- Haemonetics downgraded to Outperform from Strong Buy at Raymond James
- Haemonetics price target lowered to $72 from $87 at Baird